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1. Introduction
It is a well-known fact that effectiveness of oncotherapy in brain tumors remains under the
expectations in comparison to anaplastic tumors of other organs. Knowing the very modest
survival rates enormous efforts of neuro-oncological researches has been made, but only
partial success is produced. Beside the extremely high proliferation rate of high grade glio‐
ma cells researches established the highly intensive invasiveness and angiogenesis as the
main reasons of treatment failure. In this chapter the main molecular mechanisms of brain
tumor invasion and angiogenesis will be discussed followed by the hopeful treatment possi‐
bilities that are already in studies and will be achievable in the near-future.
2. General a spects of glioma invasion
Malignant gliomas are the most common primary brain tumors. They are associated with
the shortest survival time explained by their early recurrence due to their deep invasion of
the normal brain, which makes them practically impossible to remove completely. Invasive
anaplastic gliomas are almost invariably fatal, recurring close to the resection margin in al‐
most all cases. Interestingly, primary brain tumors have a strong tendency to invade their
environment, but with rare exceptions, do not metastasize outside the brain. [1-3].
To understand the invasion behaviour of gliomas, the cellular and molecular events of peri‐
tumoral infiltration have to be discussed. The most important medium for this process is the
extracellular matrix (ECM). The ECM comprises a considerable proportion of the normal
brain volume. The extracellular space (ECS) of the healthy brain tissue volume is approxi‐
matley 20%. The extracellular volume fraction in the majority of primary brain tumors is sig‐
nificantly increased, representing about 48% of the total tumor tissue volume especially in
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high grade gliomas. The structure and compounds of the ECM of the brain tissue have
many specific differences from other human organs. The ECM of the brain contains mainly
macromolecules like glycosaminoglycans (GAGs) and proteoglycans (PGs), and only mod‐
erately express fibrillary glycoproteins (e.g. collagens, fibronectin, elastin or reticulin). The
compounds of ECM glycoproteins play a crucial role in peritumoral invasion forming struc‐
tural elements for cellular attachment and migration. There is much evidence that ECM
components can modulate brain tumor growth, proliferation, and invasion by many differ‐
ent mechanisms. Thus extracellular matrix plays a pivotal role in the tumorous infiltration of
the surrounding tissue. The presence and functions of hyaluronic acid (hyaluronan, HA),
PGs and various types of GAGs have already been intensively investigated to clarify the
molecular mechanisms of invasion, and a positive correlation has been established many
times. To allow cell adhesion and migration, the ECM components interact with specific re‐
ceptors on the cell membrane, such as integrins, CD44, or CD168. Some proteases and syn‐
thases also strongly influence invasiveness because of their capacity to alter the actual levels
of the ECM molecules or to degrade the pericellular network. [4-16]
Using the ECM macromolecules to their active movement, glioma cells infiltrate the enviro‐
ment and form it similar to the tumor tissue. The process of the peritumoral invasion de‐
pends on the confrontation zone of the tumor cells and the non-neoplastic cells and ECM.
Glioma cells express mainly adhesion receptors and proteases, while host cells produce
macromolecules to maintain original structure and to inhibit invading cell movement. Since
brain ECM has no strong fibrillar, collagen-rich network, the brain parenchyma remains
soft, that can not hinder significantly the migration of tumor cells.
In case of glial cell tumors there are two main factors that significantly promote peritumoral
infiltration. First is the normal structure of the brain parenchyma composed mainly by tracts
in the white matter and basement membranes, which are suitable for guiding cell migration.
Second is the increased ability of glia cells to migration. Both factors are special for the brain
and they can be easily understood knowing the connection of development, structure and
function. [17, 18]
From neuro-oncological point of view the increased glioma cell mobility and extensive peri‐
tumoral infiltration leads to the following problems:
a. A. Total extirpation of a low grade tumor is not an easy and evident technical tool of
therapy. This is one main reason why these tumors are “semi-benign” tumors. Thus in
spite of the macroscopically radical surgical removal, the recurrence rate of these tu‐
mors is very high, and full recovery is not a general event.
b. B. In case of high grade tumors, neither open surgery, nor stereotactic radiosurgery can
achieve radical tumor removal. This experience can explain the local recurrence that ap‐
pears in almost every case.
c. C. Local chemotherapeutical treatment (intraparenchymal or post operatively adminis‐
tered intracavital drug) has low effectiveness.
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3. Molecular aspects of glioma invasion
Molecules that are responsible for the cell migration are divided in three groups:
1. Cell-membrane associated molecules (receptors and adhesion molecules).
2. Extracellular matrix (ECM) components (targets for the receptors).
3. Enzymes that are synthesizing or lysating the ECM components.
3.1. Cell-membrane associated molecules (receptors and adhesion molecules)
Molecules with evident role in peritumoral invasion are located either on the cell surface, or
form transmembrane structure. The main representatives of this group are the receptors and
adhesion molecules as detailed below.
The Ig superfamily contains molecules in the cell membrane consisted of immunoglobulin-
like and fibronectin type III domains involved in cell–cell adhesion. The superfamily in‐
cludes the integrins, a variety of cell adhesion molecules (CAMs) with distinct ligand-
binding specificities, namely ICAM (intercellular), NCAM (neural), Ep-CAM (epithelial), L1-
CAM, VCAM (vascular), ALCAM (activated leukocyte), and JAM (junctional adhesion
molecule), among others. [19]
The integrins are the most common molecules that serve for glioma cells to adhere to ECM.
These molecules are heterodimeric transmembrane glycoproteins consisting of non-cova‐
lently linked α and β chains, which both determine ligand binding strength and specificity.
Eight distinct α and 18 β chains combine to form about 24 different heterodimers. They can
interact with two groups of ligands: some of the ECM proteins, such as fibrinogen, fibronec‐
tin, vitronectin, and cell surface molecules, that are members of the immunoglobulin super‐
family. Regarding the many different heterodimers, each cell type maintains a specific and
activation-dependent integrin repertoire and consequence ligand preference. The cytoplas‐
mic integrin domains connect to signalling proteins and to the actin-cytoskeleton mediating
intracellular signal transduction and cell movement. This function definietly demonstrate
the dynamics of cell–ECM interaction as cells move along a substrate. Thus, integrins are
prominently important mediators for cell adhesion and migration. They also interact with
growth hormone receptors and contribute to cell–cell contacts due to direct interactions with
counterpart cell receptors. On the other hand, focal contacts mainly depend on the ECM-
compartment and on the cell type. Different integrins are known to be involved in that proc‐
ess. Integrin α5β1 binds to fibronectin, α6β1 or β4 binds to laminin, αvβ3 binds to
fibronectin, vitronectin and tenascin-C and α2β1 binds to fibrillar collagen. Some of the in‐
tegrins are directly connected to malignant behavior of gliomas. Neutralizing antibodies to
β1- and αvβ5-integrin lead to decreased glioma migration in vitro. It was also demonstrated,
that tenascin increases in vitro motility of human gliomas through interaction with β1-integ‐
rins. Inhibition of β1-integrins leads also to decreased motility, whereas inhibition of αv-in‐
tegrin causes increased motility. The integrin αvβ3 plays a central role in glioma invasion.
Increased expression of integrin αvβ3 results in increased motility of glioma cells with a de‐
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crease in apoptosis sensitivity. Furthermore, inhibition of integrin αvβ3 decreases glioma
cell motility. Integrins αvβ3 and αvβ6 interacting with tenascin was proved to mediate ad‐
hesion rather than migration. Expression of β5-integrin is correlated with in vitro invasive‐
ness and migration of human glioma cells. However α-actin expression and linkage of
integrins to the cytoskeleton is related to glioma aggressiveness and poor prognosis in WHO
II and III astrocytoma. [20-33]
Integrins mediate also activation of focal adhesion kinase (FAK) that associates with β1-
and β3-integrins, which can trigger FAK phosphorylation. It is a non receptor tyrosine kin‐
ase overexpressed in invasive glioma cells, and its expression correlates with tumor
recurrence and invasiveness in many tumor types. FAK is activated either by integrin medi‐
ated adhesion to ECM or by growth factor stimulation and it induces cell migration. Induc‐
tion of FAK can protect cells from apoptosis. [34-41]
The neural cell adhesion molecule (NCAM) is expressed mainly by developing neurons. It
is downregulated during embryogenesis and re-expressed again once differentiation is initi‐
ated. Overexpression of NCAM decreases glioma cell motility in vitro. In drug-resistant
glioma cell lines NCAM expression is reduced and integrin-expression is increased that help
to explain decreased chemosensitivity in invading glioma. [42- 45]
CD44 is the most important HA-receptor expressed by every nucleated cells in vertebrates.
CD44 is a transmembrane glycoprotein belonging to the immunoglobulin receptor super‐
family. Besides the standard form (CD44s), multiple splice variants encoded by variable
exons v1–10 (CD44v1–10) can be identified depending on the cell differentiation and activa‐
tion state. Interactions of CD44 with numerous other molecules, such as collagens, laminins
and fibronectin, have been proved in vitro. CD44 is consisted of four functional domains:
amino terminal domain, stem structure, transmembrane domain and cytoplasmic domain.
The amino terminal domain can link to the ECM components such as HA and other GAGs.
The stem structure domain binds the amino-terminal domain and transmembrane domain.
The transmembrane region is probable responsible for the association of CD44 with lipid
rafts. The cytoplasmic domain of CD44 is connected to the cytoskeleton via ankyrin and oth‐
er proteins that is necessary to cell adhesion and motiliy. CD44 can be cleaved to two parts,
and both the extracellular and intracellular components of CD44 promote cell migration.
CD44 also interacts with various regulatory mediators to cell signaling pathways. Through
these connections CD44 promotes MMP-mediated matrix degradation, tumor cell growth,
migration and invasion and its expression correlates well with invasion potential of glioblas‐
toma. [46-54]
The receptor for hyaluronate-mediated motility (RHAMM) is also a HA-binding protein
expressed on the cell surface and also in the cytoplasm, cytoskeleton and nucleus. Interac‐
tion of HA with RHAMM induces many cellular signaling pathways in connection to pro‐
tein kinase-C, FAK, MAP kinases, NFκB, RAS, phosphatidylinositol kinase (PI3K), tyrosine
kinases and cytoskeletal components. CD44 and RHAMM probably have redundant or
overlapping functions, but it is evident that interactions of HA with CD44 and RHAMM are
necessary for tumorigenesis and tumor progression. [55-58]
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Syndecans are a family of transmembrane heparan sulphate proteoglycans with four mem‐
bers, syndecans 1 to 4. Syndecans are co-receptors by binding their ECM ligands in conjunc‐
tion with other receptors, mainly integrins. Through their heparan sulphate side chains,
syndecans may further take part in other ligand binding, like VEGF, fibronectin and antith‐
rombin-1. Linking syndecan to fibronectin is modulated by tenascin-C. Syndecan-1, -3, and
syndecan -2, -4 bild two different structural subgroups. Syndecan-1 is expressed generally in
fibroblasts and epithelial cells (especially in keratinocytes), but normally there is only a
moderate presence in endothel and neural cells. Syndecan-3 dominates in neural cells, but
not in epithelial cells, and syndecan-4 can be found mainly in epithel cells and fibroblasts,
while it is poorly expressed by endothel and neural cells. Syndecans have four main func‐
tion: 1. activation of growth hormon receptors; 2. cell adhesion to ECM components such as
collagens type I, III, V, fibronectin, thrombospondin and tenascin; 3. cell-to-cell adhesion
(e.g. syndecan-4 and integrin linkage takes part in intercellular interactions; 4. tumor sup‐
pression (anti-invasive effect by keeping tumor cells together) or tumor progression (de‐
pending on tumor histology and growth phase). [59-62]
Cadherin superfamily is also an important group of adhesion molecules regarding glioma
invasion. Cadherins are transmembrane proteins compound of several tandemly repeated
cadherin domains that interact in calcium-dependent homophilic cell–cell contacts. The cad‐
herin superfamily consists of more than 100 different members, with E- (epithelial) and N-
(neural) and P-cadherin, most intensively expressed in epithelial and neural tissues,
respectively. Desmosomal cadherins (desmoglein and desmocollin) provide a linkage to the
intermediate filament network through connection with cytosolic proteins (desmoplakin,
plakoglobin and plakophilin). Adherens junctions play a pivotal role in embryonic develop‐
ment as well as in the maintenance of tissue architecture in adults. Cadherins are linked to
the actin-cytoskeleton network through catenins (α-, β-catenin, plakoglobin and p120ctn),
thereby providing molecular lines of communication to other cell–cell junctions and to cell-
substratum junctions. Cadherin cluster forms a transmembrane core of adherens junctions at
sites of the cell–cell contacts. During tumor progression decreased cadherin function is cor‐
related with de-differentiation, metastasis and poor prognosis. In glioblastoma N-cadherin
cleavage is regulated by ADAM-10 that promotes tumor cell migration. Furthermore, aber‐
rantly processed proN-cadherin promotes cell migration and invasion in vitro, and in hu‐
man glioma the level of proN-cadherin is elevated that directly correlates with the invasion
potential. [63-68]
Dystroglycan is a transmembrane glycoprotein expressed mainly in sceletal muscle cells,
but it can be also found in brain tissue as well. Its main function is to creat contact between
the ECM macromolecules and the intracellular cytosceleton. It is linked intracellularly to
dystrophin, a protein coded on the X-chromosome (lack of dystrophin causes the herediter
muscle disease named dystrophia musculorum Duchenne). Dystroglycan is a heterodimeric
complex consisting of non-covalently associated α and β subunits. The α-subunit connects
α2-laminin, agrin and perlecan (components of the lamina basalis), the β-subunit is the
transmembrane part that binds to dystrophin. Overexpression of dystroglycan decreased
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the growth rate of glioma cell lines so it was found to be involved in the progression of pri‐
mary brain tumors. [69-71]
3.2. Extracellular Matrix (ECM) components (targets for the receptors)
Various components of brain ECM, like GAGs and PGs are overexpressed in gliomas. These
molecules are binding sites for tumor cell receptors or they can inhibit cell migration, so
they take an important part in peritumoral glioma invasion, and consequently could also
serve as targets for anti-tumor therapy.
Proteoglycans (PGs) are composed of a protein core and glycosaminoglycan side chains
(GAGs). GAGs are carbohydrate polymers containing N-acethylglucosamine or N-acethyl‐
galactosamine and uronic acid (glycuronacid or iduronacid).
Depending on the GAG side chains the main types of PGs are chondroitin-sulphate (gly‐
curonacid  and  N-acethylgalactosamine  polymer  and  protein  core),  dermatan-sulphates
(former  name  chondroitin-sulphate-B,  composed  of  iduronacid  and  N-acethylgalactosa‐
mine  polymer  and  protein  core),  heparansulphate  (glycuronacid  and  N-sulphoglucosa‐
mine  polymer  and  protein  core)  and  keratansulphate  (galactose  and  N-
acethylgalactosamine  polymer  and  protein  core).  Hyaluronic  acid  (hyaluronan,  HA)  is
consisted of only GAGs (glycuronacid and N-acethylglucosamin polymer) that has no co‐
valent bind to a protein, so it is not a PG by definition, but due to its tight relation to the
PGs in general it is discussed together with them.
One of the most frequent adhesion glycoprotein in the ECM is fibronectin. It has a pivotal
role in cell attachment, migration, differentiation and proliferation. Although its protein
fragment is coded by only one gene, more isoform exits due to alternative splicing. The
main cell surface receptors for fibronectin are the integrins, but it can also bind collagens,
fibrin and heparan-sulphates. It is structured of two different subunits linked by disulphid
bridges to each other. Fibronectin appears in two different forms: the solubile molecule can
be found in the plasma, produced by hepatocytes, it accumulates at wessel wall damage and
has an evident role in clot-building. The insolubile form of fibronectin is expressed by fibro‐
blasts and mainly localized in the intercellular ECM. In tumor stroma production of fibro‐
nectin is reduced and its degradation is increased. Paralel to these changes on tumor cell
surface, the expression of the fibronectin receptor α5β1 integrin is also decreased. ECM com‐
ponents such as fibronectin and collagen type IV are mostly produced by the host tissue and
are associated dominantly with the vessel walls in gliomas. Fibronectin is mainly degraded
by MMP-2 that is specifically active in gliomas explaining partly the moderate presence of
extracellular fibronectin in glioma ECM. [72-74]
Another common component of the ECM is the molecular family of laminins. This glyco‐
protein has many variants, and it is the main component of lamina basalis. It is thought to
take part in cell differentiation, adhesion, migration and cell survival. Each molecule of lam‐
inin consits three different chains (α, β, and γ chain) which has 5, 4 and 3 genetic variants,
respectively. Recently at least fifteen different chain-combinations have been detected in hu‐
man tissues. In the lamina basalis laminins promote cell-to-cell linkage, and it forms a spe‐
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cific network with connection to enactin, fibronectin and perlecan. These molecules can also
bind to cell surface receptors such as integrins or dystroglycans, etc. Laminins regulate glio‐
ma cell adhesion to ECM proteins in specific manner leading to cell proliferation or cell mi‐
gration and up-regulation of laminin is associated with the invasiveness activity. [75-77]
Agrin is also an ECM forming PG with the capability to collect acetylcholin receptors. Nor‐
mally it is indispensible in developing neuromuscular junctions during embryogenesis. Ag‐
rin is secretaed at the end of the moto-neurons, and it is also a main component of
membrana basalis in various human organs taking part in cell-ECM interactions. Together
with neurocan, tenascin-C and versican it is responsible for the peritumoral infiltration of
gliomas. [78]
Hyaluronan(HA) is a non-sulphated, linear, high-molecularweight GAG. It differs evidently
of other GAGs, because of its extremely large molecular weight (103–104 kDa) composed of
10,000 or more disaccharide repeating units, the lack of sulfate groups or epimerized uronic
acid residues and because HA is synthesized at the inner face of the plasma membrane as a
free linear polymer without any protein core. It has a significant waterbinding capacity, so it
controls the water content of the brain interstitium. HA comprises a substantial fraction of
brain ECM and is involved in many physiological and pathological processes. In normal
ECM, HA sustain tissue homeostasis, biomechanical integrity, structure and some kind of
tissue cohesion. In malignant tumor tissues, HA transmit signals into cytoplasm and induces
cell proliferation, motility and invasion. HA binds tenascins, lecticans, the cell surface recep‐
tors including CD44, RHAMM or ICAM-1, which together contribute to ECM organization
and cell–matrix interaction. Through elevating the level of MMP-9 HA also promotes peritu‐
moral invasion by activating the protease system. Glial tumors have increased amounts of
HA which facilitates invasion activity of glioma cells. [79-84]
Lecticans comprise also a family of chondroitin sulphate proteoglycans with four members
(brevican, versican, neurocan, and aggrecan), whereby brevican and neurocan are brain-spe‐
cific molecules. Lecticans contain HA and tenascin binding sites and thus mediates linkage
in protein–PG-GAG networks. [85-86]
Brain enriched hyaluronan binding (BEHAB) molecule,also known as brevican, a brain-
specific chondroitin sulfate PG shows dramatic upregulation in gliomas and it is also in‐
duced during periods of increased glial cell motility in development and following brain
injury. Gliomas express unique brevican isoforms and the processing of this specific isoform
is important for its proinvasive role. In experimentally induced tumors brevican accumu‐
lates at the invasive borders and it associates with high infiltrative profiles. Furthermore,
brevican up-regulation correlates well with short survival periods of patients with high
grade gliomas. Brevican expression in gliomas is restricted to membrane localization, and its
presence in high-grade gliomas suggests that it plays a significant role in glioma progres‐
sion. Brevican promotes activation of epidermal growth factor receptor (EGFR), increases
the synthesis of cell adhesion molecules and facilitate fibronectin microfibrill presence on
the cell membrane. The effect of brevican on glioma cells motility is mediated not only via
EGFR signaling but also by fibronectin-dependent adhesion, and increased expression of
CAMs. This motogenic signals could not be worked in the normal neural ECM, where fibro‐
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nectin is almost absent but it is effective in the microenvironment of glioma cells, which co-
express large amounts of brevican and fibronectin in vivo. This interaction explains the
distinct ability of these tumors spreading in the central nervous system. Overexpression of
brain-specific isoforms of brevican proved to be correlated with ability to peritumoral inva‐
sion of gliomas. [73, 87-89]
Neurocan is a large brain specific chondroitin-sulphate PG that interacts with heparan-sul‐
phate proteoglycan (HSPG) molecules, such as syndecan-3 and glypican-1. It has influence
on cell adhesion and migration. Neurocan has two HSPG-binding domain with different af‐
finity. In cell culture neurit outgrowth is increased by C-terminal part of neurocan. HSPGs
serve also as cell-surface receptors for neurocan, and connection of neurocan to the HSPGs is
necessary for the neurit growth. It was found on clinical samples that higher expression of
neurocan is associated with the invasive activity of astrocytomas. [89-90]
The ECM glycoprotein tenascin, which forms a hexabrachion structure, can be detected in
both the ECM and the perivascular tissues of high-grade gliomas. Tenascin R, a brain-specif‐
ic member of the tenascin family comprising also tenascin C, X, and W, is a homotrimer
with both lectican and integrin binding sites forming an adhesion link between the ECM
and cells. The developed brain does not contains tenascin, but in normal brain tissue distin‐
guishable deposits of this glycoprotein can be found in the glia limitans externa, and some
tenascin was also detected in the ECS of white matter. Theres is a positive correlation be‐
tween tenascin production and the malignancy or angiogenesis of astrocytomas and there is
a prognostic utility of its immunohistochemical detection in ependymomas. The accumula‐
tion of tenascin in the ECS in high grade glial tumors can be one of the major factors leading
to the critical increase in ECS tortuosity and the simultaneous enlargement of the ECS. It has
been arised that the ECM distribution is modified at the brain-tumor zone of confrontation
and the presence of tenascin in this zone represents a negative prognostic factor in pediatric
ependymomas. Tenascin-C is overexpressed in both low and high grade astrocytomas as
well. In cultured brain-tissue tenascin-C is produced by the endothelial cells. It takes an im‐
portant part in various cellular mechanisms like heamagglutination, T-cell immunsuppres‐
sion, angiogenesis, chondrogenesis and it also has some antiadhesive effect. Tenascin
subunits contain EGF- and fibronectin-like repeated sequences that are responsible for the
growth inducing effect. Tenascin-C enhances migration of endothelial cells and phosphory‐
lation of focal adhesion kinase (FAK). Tenascin-C signaling is mainly mediated by integrin-
β1 which interacts with FAK. Tenascin-C is produced by the glioma cells rather than by the
invaded brain and it improves aggressive behaviour and invasion activity of grade II astro‐
cytoma cells in vitro and in vivo. Furthermore, expression of tenascin-C can be used as prog‐
nostic factor in grade II astrocytomas showing correlation with ability of tumor recurrence.
Beside this, low tenascin-C expression was found to be associated with prolonged average
survival time in glioblastomas and highest tenascin-C expression could be detected at the
border of the malignant gliomas. [91-104]
Versican (also known as VCAN or CSPG2), a chondroitin sulfate PG, is one of the main
components of the ECM, expressed almost in all human tissues. Versican takes part in nor‐
mal tissue development, but its increased expression can be also detected in most malignan‐
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cies. Elevated versican production occurs in either the tumor cells or the stromal cells
surrounding the tumor. Increased versican expression strongly correlates with poor out‐
comes for many different tumor types. Versican regulates a wide variety of intracellular
processes including cell adhesion, proliferation, apoptosis, migration and invasion via the
chondroitin and dermatan sulfate side chains. In addition, the versican G1 and G3 domains
can interact with various intracellular or extracellular molecules. In addition to HA, versican
associates with tenascin-R, fibulin-1 and -2, fibrillin-1, fibronectin, P- and L-selectin, and
many chemokines. It also binds to cell surface proteins including epidermal growth factor
receptor (EGFR), CD44, and integrin β1.
A number of proteinase families are capable of generating the proteolytic fragments of versi‐
can. Matrix metalloproteinase (MMP)-1, -2, -3, -7, and -9, ADAMTS-1, -4, -5 and -9 cleave
versican and generates proteolytic fragments.The accumulation of proteolytic fragments of
versican play an important role in cancer progression. The regulation of G1 and G3 versican
levels by proteases is known to be important in regulating cancer cell motility and metasta‐
sis. Through the EGF-like motifs in the G3 domain versican can stimulate cell proliferation
and its G1 domain destabilizes cell adhesion and promotes cell growth. Versican expression
is associated with a high rate of proliferation and it is localized in HA-rich tissues and also
accumulated in perivascular elastic tissues involved in peritumoral invasion. These features
of versican make it a proliferative, anti-adhesive and pro-migratory molecule that facilitates
tumor cell motility. In clinical samples the association of versican to invasiveness of astrocy‐
toma could be evidently demonstrated. On the other side, the decreased expression of versi‐
can V0 and V1 isoforms in glioma ECM can be related to the marked local invasivity and
rarity of extracranial metastasis of gliomas. [105-111]
3.3. Enzymes that are synthesizing or lysating the ECM components
Matrix metalloproteinases (MMPs) are the most common proteases that degrade ECM to
create the space for invading glioma cells. MMPs belong to the zinc-dependent endopepti‐
dase together with adamalysins, serralysins and astacins. MMPs take part in remodelling af‐
ter tissue damage, cell migration, differentiation and angiogenesis. At least 28 different
types of MMPs are identified composing a protease family that is able to degrade practically
every component of the ECM. Due to their function, MMPs also play evident role of activat‐
ing mechanism by cleavage metabolits of inactive molecules. MMPs are overexpressed in
glioma cells compared with normal brain tissue. MMP-2, MMP-3 and MMP-9 activity corre‐
lates well with glioma cell migration and invasion. [46, 112, 113]
Cathepsin-B is a cystein protease involved in protein degradation primarily within intracel‐
lular lysosomes but it takes evidently part in degradation of ECM-proteins. In order to be
able to interact with ECM proteins, the lysosomal enzyme is secreted from its intracellular
localization. Thus cathepsin B appears on the surface of glioma cells, where the enzyme can
interact with the surrounding matrix components. Cathepsin-B is overexpressed in gliomas.
Downregulation of cathepsin B in human glioma cells leads to decreased invasiveness in
matrigel-assay and coculture experiments. Furthermore, downregulation of cathepsin-L in
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human glioma cells correlates with decreased invasiveness and increased sensitivity to
apoptotic stimuli. [114-118]
4. Invasion process of tumor cells
Knowing the invasion potential of primary brain tumors, many of the molecular mecha‐
nisms of peritumoral infiltration have been already studied and some of the invasion proc‐
esses have been defined. During malignant transformation, invasiveness is determined by
the complex functions of tumor cells of distinct histological types. A four-step model of in‐
vasion has been applied, that is also valid for brain tumors. This model contains the follow‐
ing steps: 1) the tumor cells at the invasive site detach from the growing primary tumor
mass; 2) they adhere to the extracellular matrix (ECM) via specific recebptors; 3) proteases
secreted by the glioma cells locally degrade the ECM components, forming a pathway mi‐
gration into the surrounding tissue, and 4) tumor cell movement due to cytosceletal process‐
es. Each step of the peritumoral invasion requires a harmonized cooperation of numerous
molecules resulted in active cellular movement into the normal brain parenchyma. [119, 120]
The detachment of invading glioma cells from the primary tumor mass is a complex process
comprising the following steps: 1) Destabilization and disorganization of the cadherin medi‐
ated junctions that hold the primary mass together. 2) Decrease expression of cell adhesion
molecule which provides adhesion to the primary tumor mass. This leads to a reduction in
gap junction formation. Cell–cell communication is necessary for growth control and differ‐
entiation, and it is mainly achieved through gap junctions. Increased malignancy of gliomas
is accociated with reduced in situ gap junction formation, and invasion of gliomas. 3) Cleav‐
age of CD44, which anchors the primary mass to the ECM. This process is mediated by met‐
alloproteinase ADAM. [119-123]
Tumor cell adherence to the ECM components is mediated by specific cell surface or trans‐
membrane receptors like integrins binding to laminins, fibronectins and collagens or CD44
to hyaluronan.
Degradation of ECM components occurs due to the local enhancement and activation of
protease suc as MMPs, hyaluronidase, cathepsins and chondroitin suphatase.
Due to migration the glioma cell must interact with the surrounding ECM, which forms a
mechanical barrier to the cells, and serves as a substratum for traction for the moving cells.
For cell movement changes in cell morphology occur: the cell becomes polarized and mem‐
brane protrusions develop, including the extensions at the leading edge of pseudopodia, la‐
mellipodia, filopodia, and invadopodia. These extensions contain filamentous actin and
various structural and signaling molecules. The formation of membrane anchors needs cy‐
toskeletal contraction, which finally results a cell forward displacement. Glioma cell motility
and contractility also require A and B isoforms of myosin II. Myosin II is the major source of
cytoplasmic contractile force. Myosin II allows glioma cells to squeeze through pores small‐
er than their nuclear diameter, which is especially important for gliomas because the human
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications12
brain tissue has particularly narrow extracellular spaces. The connection of ECM macromo‐
lecules and cytosceleton is mediated by dystroglycans. [69, 124]
5. The possible agents for antiinvasive therapy
Tumor cell invasion into the surrounding brain tissue is mainly responsible for the failure of
radical surgical resection and successful treatment, with tumor recurrence as microdissemi‐
nated disease. ECM related molecules and their receptors predominantly participate in the
invasion process, including the cell adhesion to the surrounding microenvironment and cell
migration. Determination of the key molecules of invasion process can help toprovide possi‐
ble targets for antiinvasive therapy. Regarding peritumoral infiltration activity of glioma
cells, the following molecules are supposed to serve as antitumor agents.
Cilengitide is a cyclic peptide targeting the RGD-motif of integrins blocking αvβ3- and
αvβ5-integrin mediated interaction between endothelial cells and ECM. By targeting these
integrins cilengitide could inhibit both glioma invasion and angiogenesis. Cilengitide causes
significant regression of glioma xenograftsand induces apoptosis in U87 glioma cells cul‐
tured on tenascin and vitronectin. In clinical trials targeting glioma invasion, in a random‐
ized phase II study cilengitide proved to be safe and was associated with a median survival
of 10 months in recurrent glioma patients. The North American Brain Tumor Consortium
(NABTC) study aimed to determine cilengitide penetration rate into GBM in human pa‐
tients. This study confirmed that cilengitide is effectively delivered into primary human
GBM tumors with good retention. The effect of combination therapy, such as cilengitide
with XRT or with another chemotherapeutic agent, is likely to be cumulative. [125-129]
Knowing the evident role of versican proteolytic fragments in cancer progression, its possi‐
ble role as target for anti-cancer therapy has been arised. Although there are only a few re‐
sults regarding anti-versican therapy in glioma patients, some possible agents are notable to
mention for their potential future role.The tyrosine kinase inhibitor genistein has been
shown to block versican expression in malignant mesothelioma cell lines and in vascular
smooth muscle cells. Versican G3 fragments facilitate cancer cell growth, invasion and meta‐
stasis through EGFR signaling. The selective EGF receptor inhibitor, AG1478 prevents G3
fragment enhanced cell growth, migration, invasion and chemical resistance in vitro. Galar‐
din, an antibody against the ADAMTS specific versican cleavage site inhibits glioma cell mi‐
gration. GM6001, a MMP and ADAMT proteases inhibitor, also decreases cancer cell
invasion and metastasis in several kinds of carcinoma. Other protease inhibitors such as cat‐
echin gallate esters, present in natural sources (green tea) selectively inhibit ADAMTS-1, -4
and -5 catabolism. [130-137]
Tumor  formation  of  the  pericellular  matrix  with  HA  and  versican  can  be  inhibited  by
treatment with HA oligomers, which can block the interaction between HA and versican,
serving as inhibitors of cancer dissemination. Furthermore, disruption of the HA CD44 in‐
teraction  with  HA  oligomers  could  also  inhibit  the  growth  of  B16F16  melanoma  cells,
Therefore the application of HA oligomers can be an effective agent for inhibiting the for‐
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mation  of  vesicant-HA-CD44  complexes,  providing  valuable  targets  against  tumor  pro‐
gression. [138-140]
Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) has evident anti-invasive effect on HA-
induced glioma invasion. In glioma cells emodin inhibits the TGFbeta and FGF-2 induced
expression of syndecan-1. It decreses the expression of MMP-2 and MMP-9 at both tran‐
scriptional and translational levels suggesting that emodin can be a clinically valuable anti-
cancer agent against glioma invasion. [141, 142]
Since increased MMP levels are associated with glioma invasion and angiogenesis, marima‐
stat, an orally active drug that can reduce MMP levels in patients with gliomas could inhibit
growing of tumor. A phase II study evaluated marimastat combined with temozolomide
(TMZ) in patients with recurrent malignant glioma and good outcome was documented, but
joint and tendon pain was reported in 47% of patients. [143, 144]
6. General aspects of angiogenesis
Rapidly growing tumors need to develop their own vasculature. The hypervascularisation
of high grade gliomas can be visualized well on radioimaging and it can be a preoperative
characteristic of glioblastoma. Furthermore, glioma angiogenesis is necessary for tumor ex‐
pansion and survival, so its inhibition could be a potential tool in anti-tumor therapy.
There are two main angiogenic and invasive glioma phenotypes. Clusters of glioma cells
perform single cell infiltrations into normal parenchyma independent of vasculature. An‐
other group of glioma cells can be found around newly developed vessels in the normal
brain parenchyma near to the tumor margin. These two different angiogenic and invasive
phenotypes  are  called  angiogenesis-dependent  and  angiogenesis  independent  invasions.
High  grade  astrocytomas  content  both  invasion  phenotypes  in  a  mixture  of  subclones
present in different intratumoral regions.  Molecular mechanisms of single cell  migration
were detailed above, but the role of neo-angiogenesis forms also a very important way to
glioma expansion. [145]
In expanding, highly proliferate gliomas angiogenesis is activated when the pro-angiogenic
stimuli dominates over the anti-angiogenic stimuli. These stimuli are mediated by factors se‐
creted from glioma, endothelial or microglia cells, or arise from the extracellular matrix or
other environmental sources like hypoxia induced cell productions. The pro- and anti-angio‐
genic forces are influenced strongly by tissue hypoxia and genetic alterations. The summa‐
tion of these stimulileads to the so-called “angiogenic switch” in glioma angiogenesis.The
most effective activator of angiogenesis in brain tumors is hypoxia that downregulates anti-
angiogenic pathways and induces many pro-angiogenic ones. A well-known pathway is the
HIF-1/VEGF-A pathway, which play a significant role in endothelial cell proliferation and
migration. Another pathway mediator is interleukin-8, which is produced by microglia cells
as a reaction to hypoxia. It is important to mention, that genetic instability of high grade
gliomas provides the way of angiogenesis independently of hypoxia (such as chronic HIF
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications14
activation via phosphoinositide 3-kinase (PI3K) or mitogenactivated protein kinase (MAPK)
pathways. [146-152]
After activating the “angiogenic switch”, the tumor produces new vessels. The modes of
new blood vessel formation in glioma occur by one of three different methods: 1) angiogene‐
sis; 2) vasculogenesis; or 3) arteriogenesis. Angiogenesis is the formation of new blood ves‐
sels by rerouting or remodeling existing tumor vessels, and is supposed to be the main
stream of neo-angiogenesis. Vasculogenesis means de novo production of blood vessels
from circulating marrow-derived endothelial progenitor cells originally as the method of
vasculature development in embryonic process. Since these progenitor cells have been also
identified in tumors, they role in tumor angiogenesis cannot be denied. Vasculogenesis is
probably regulated by tumor-secreted stromal-derived factor 1 under the control of the hy‐
poxia-induced transcription factor hypoxia-inducible factor 1α (HIF1α). Arteriogenesis is
the third mode of arteriolar networks formation representing a moderate proportion of tu‐
mor angiogenesis. [153-156]
6.1. Neoangiogenesis
The most significant way to form new blood vessels in gliomas is neoangiogenesis. Forma‐
tion of new vessels from native vessels begins with breaking down the original vessel wall.
The process of blood vessel breakdown is composed of three main phases. The first event in
forming new vessels from existing ones is the disintegration of the vessel wall. Angiopoie‐
tin-1 (Ang-1) and its receptor Tie-2 play a pivotal role in this phase. Normally, Ang-1 binds
to Tie-2 achieving a close association between pericytes and endothelial cells that is necessa‐
ry for vasculature stability. In rapidly proliferating tumors like glioblastoma, tissue hypoxia
increases and it induces Ang-2 upregulation in endothelial cells whereas Ang-1 is accumu‐
lated tumor cells. Increased Ang-2 expression, which is an antagonist of Tie-2, leads to the
initial regression of blood vessels. Beside these, matrix-metalloproteinase (MMP)-2 expres‐
sion is induced via Tie-2 signaling, and in conjunction with VEGF promotes angiogenesis.
The second phase is the breakdown of ECM to provide place for the migration of endothel
cells to form new blood vessels. Following dissolution of native vessel wall, degradation of
the vessel basement membrane and relating ECM is the necessary condition for endothelial
cells for invasion the surrounding microenvironment. MMPs play an integral role in this
phase. In case of glioma angiogenesis, the collagenases MMP-2 and MMP-9 are involved in
this process and their expression correlates with a poor prognosis in gliomas. Expression of
MMP-2 and MMP-9 is also induced by hypoxia and through their proteolytic activity inter‐
action of endothelial cells and tumor-ECM contents like VEGF and fibroblast growth factor
(FGF) occurs. [157-166]
The third phase to form new blood vessels is the migration of endothelial cells. After disso‐
lution of the basement membrane of the blood vessels and decomponent ECM, endothelial
cells begins to proliferate and migrate toward tumor cells that expresses pro-angiogenic fac‐
tors. Due to this process cell surface adhesion and migration molecules, such as integrins
and CD44 upregulates.The activated endothelial cells secrets platelet-derived growth factor
(PDGF) that induces pericytes to participate in creating a new basement membrane. For this
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reason beside migration of endothelial cells, pericyte migration also occurs as a necessary
event of vasculogenesis. [167-169]
At the end of tumor blood vessel formation a significant change occurs in the extracellular
environment, caused by increased expression of embryonic ECM molecules, such as tenas‐
cin-C. Elevation of VEGF and Ang-2 levels can be also detected, that probably explains the
leakiness and pathologic structure of the new vessels. The result of glioma angiogenesis are
highly tortuous dilated vessels and lots of small diameter vessels with alterations in endo‐
thelial cell adhesion molecule expression and disrupted basement membrane. [170-174]
7. Molecular aspects of glioma angiogenesis
Angiogenesis is mainly induced through growth hormone receptors, especially through the
vascular endothel growth factor receptor (VEGFR). This is a transmembrane receptor with
an extracellular antibody-binding domain (for vascular endothel growth factor (VEGF)) and
an intracellular tyrosin kinase domain stimulating the PI3K/Akt pathway. In tumor angio‐
genesis the effect of VEGFR can be increased either by receptor overexpression on the cell
surface or by mutation of the receptor that without a hormone-ligand or by only a moderate
ligand connection it keeps on a permanent stimulus.
Regarding glioma angiogenesis not only VEGFR but the hormone ligand VEGF has also an
evident role in the process. There are more types of VEGF. Specifically, VEGF-A is upregu‐
lated in glioblastoma and it is produced by many cell types, such as tumor cells, stromal,
and inflammatory cells. VEGF-A is primarily induced by tissue hypoxia and it regulates en‐
dothelial cell survival, proliferation, permeability and migration mainly through the VEGF-
receptor 2 (VEGFR2). VEGF can also be derived from the tumor-ECM. Beside the increased
amount of VEGF, the receptors VEGF-R1, VEGF-R2 and VEGF-R3 are upregulated on endo‐
thelial cells in glioma in comparison to normal brain. [175- 182]
Other growth factors have also influence on angiogenesis. Epidermal growth factor (EGF),
basic fibroblast growth factor (bFGF) and platelet derived gfrowth factor (PDGF) facili‐
tates VEGF expression. The result of pathologic increased VEGF signaling in tumors is im‐
mature, highly permeable blood vessels with deteriorated blood-brain-barrier (BBB)
function and subsequent parenchymal edema. In glioma, bFGF is expressed by tumor cells
and endothelial cells but it can be also accumulated and stored in the extracellular matrix of
glioma. [183-186]
In rapidly proliferating anaplastic gliomas oxigene supply remains constantly under the ne‐
cessity, thus hypoxia remains a permanent stimuli for angiogenic factors. It seems to induce
not only the secretion of growth factors, but also interleukin-8 (Il-8), a chemokine released
by microglia, and Il-8 is expressed in adult glioma at levels correlating to tumor grade. In
glioma the interleukin-8 mediated angiogenesis is regulated by the tumor suppressor pro‐
tein ING4 through the transcription factor NFĸB. [187-189]
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Interestingly, there are some molecules involved in neuronal pattering during embryogen‐
esis  that  have  similar  functions  in  vascular  pattern  during  tumor  angiogenesis.  One  of
these molecules is the semaphorin, that induces signal pathway through neuropilins and
plexins. Neuropilins are expressed on vascular endothelial cells and function as receptors
for  VEGF.  Their  activation  leads  to  pro-angiogenic  responses  even in  the  absent  of  the
classical  VEGF-R2 signaling  and blocking neuropilin-1  can decrease  tumor  angiogenesis
and growth. [183, 190-192]
Beside growth factors and their receptors, there are some ECM components that are overex‐
pressed in glioma vessels in comparison to normal brain tissue, and have some stimulating
effect on angiogenesis. One of the most important ECM proteins with an evident role in an‐
giogenesis is tenascin-C, which is normally not expressed in the adult brain, but in glioma it
can be found at the invading tumor border in the region of angiogenesis. Tenascin-C facili‐
tates endothelial cell migration and induces VEGF expression and focal adhesion kinase
phosphorylation, which are both important for angiogenesis. Another ECM protein in‐
volved in angiogenesis is fibronectin. The oncofetal form of fibronectin is typically only ex‐
pressed during embryogenesis, but it is also produced in GBM, and it is localized to the
tumor vessels. Laminin-8 a member of the laminin family in ECM is expressed in vascular
basement membrane of GBM. Its blocking in an animal model of GBM resulted in decreased
tumor microvessel density and increased survival. Versican is also an important ECM com‐
ponent of the tumor angiogenesis process. The versican G3 domain facilitates endothelial
cell adhesion, proliferation, and migration in vitro and blood vessel formation in nude
mouse tumors. Furthermore, G3-domain expressing cells produce increased levels of fibro‐
nectin and VEGF, suggesting their common functions in angiogenesis. [193-197]
8. The possible agents for anti-angiogenic therapy
Since VEGFR play the most significant role in tumor angiogenesis, its inhibition bears the
most effective possibility for decrease tumor growth. The VEGFR is a transmembrane tu‐
mor cell  receptor,  so  blocking antibodies  could close down its  effect.  On the other  side
blocking the intracellular  tyrosine-kinase domain could also inhibit  the activation of  the
signaling pathways. The latest way came into the front in past few years, when small-mo‐
lecular tyrosine kinase inhibitors proved to be effective in vitro against glioma cell lines.
Beside these, blocking the VEG-factor itself can also definitely decrease the stimulating ef‐
fect of the receptor.
8.1. VEGF-blocking
The most known VEGF neutralizing antibody is the bevacizumab that is already a possible
tool of the oncotherapy for glioblastoma. In recurrent glioma patients treated with bevacizu‐
mab combined with the chemotherapy agent irinotecan the median survival can be pro‐
longed. As the result of a significant antitumor effect 63% radiographic response, 6-month
progression-free survival in 32% of GBM patients could be achieved. Based on these favora‐
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ble observations further clinical trials have been initiated to combine bevacizumab with te‐
mozolomide, the current standard of care for newly diagnosed glioblastoma patients.
Another clinical trial suggests that the presence of tumor hypoxia markers predicts probable
radiographic response and better survival of patients treated with combinant chemotherapy
of bevacizumab and irinotecan. Gliomas treated with bevacizumab often appear as nonen‐
hancing infiltrating laesions on MRI proving the reduced vascularity beside the ongoing in‐
vasion, so induction of anti-angiogenic therapy combined with anti-invasive therapy seems
to be a possible treatment method in the future. [198-203]
8.2. VEGF-receptor blocking
Anti-angiogenic therapy with VEGF receptor inhibitor sunitinib normalizates tumor vascu‐
lature, so it elevates intratumoral level of temozolomide due to the improved vessel func‐
tions. Cediranib is a pan-VEGFR tyrosine kinase inhibitor, while enzastaurin is a protein
kinase-C inhibitor. Both agents are already in studies. Sorafenib is a multikinase inhibitor,
that suppresses angiogenesis by inhibiting VEGFR and PDGFR activities in endothelial cells.
Sorafenib-treated mice showed significant suppression of glioblastoma cell proliferation, in‐
creased apoptosis and autophagy, and reduction of angiogenesis in vivo, phase II trials of
sorafenib in patients with malignant gliomas were inducted. Imatinib is a kinase inhibitor
of PDGFR, c-kit, and bcr-abl. In vitro studies of imatinib on glioma cell proliferation de‐
scribe, that it is cytostatic agent at low concentration whereas at high concentrations it has
cytotoxic effect. Imatinib monotherapy against malignant gliomas has failed to show any
significant clinical benefits probable because of the moderate drug penetration across BBB
and the inhibition of PDGFR alone can be insufficient to inhibit growth of malignant glio‐
mas. In spite of these its use in combination therapy is still an interesting theme. [204-211]
8.3. Other target molecules for anti-angiogenic therapy
Tenascin-C is mainly expressed in hyperplastic vessels and it promotes migration of endo‐
thelial cells in astrocytic tumors. Therefore, blocking tenascin with an antibody to inhibit an‐
giogenesis seems biologically reasonable, so a tenascin-specific antibody radiolabeled with
I-131 was tested in patients with high-grade gliomas. The phase II studies with tenascin-
blocking antibody in malignant glioma reported about a slight increase in survival time.
[101, 195, 212-214]
Another ECM protein that has anti-angiogenic effect in glioma is secreted protein acidic and
rich in cysteine (SPARC), also known as osteonectin or BM-40. Osteonectin takes part in a
number of basic biologic functions, including migration, proliferation, and survival. Expres‐
sion of SPARC in the nervous system is restricted normally to the angiogenic microvascula‐
ture, such as in the region of locus coeruleus and retinal astrocytes, but is not expressed in
the cerebral cortex. In contrast, osteonectin is present in both tumor cells and endothelial
cells in gliomas of all grades, and it is also expressed by endothelial cells and astrocytes in
the adjacent tissue. Osteonectin suppresses tumor angiogenesis via inhibition of VEGF ex‐
pression and secretion. [215-221]
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8.4. Endogenous anti-angiogenic factors
A number of endogenous anti-angiogenic factors have been described that play pivotal role
in tumor angiogenesis. Identifying these factors could offer some anti-cancer agent for neu‐
ro-oncological therapies. One of the best known endogenous anti-angiogenic proteins is an‐
giostatin. It is mainly derived from degradation of plasminogen by proteases cathepsin-D
and MMPs. In vivo studies in mice proved that angiostatin inhibits glioma angiogenesis and
growth. The thrombospondins (TSPs) are another family of proteins that serves as an anti-
angiogenic factor. In normal tissue TSP1 is produced by platelets, endothelial cells, and
smooth muscle cells. Similar to angiostatin, endostatin is also an anti-angiogenic molecule
created in glioblastoma basement membrane by proteolytic cleavage of collagen-18 by elas‐
tase, cathepsin-L, and specific MMPs. The endostatin-mediated signaling has more angio‐
genic inhibitory mechanism by binding to a5b1 integrin, inhibition of VEGF-R2, reduction of
focal adhesion kinase-mediated endothelial cell migration, and suppression of pro-angio‐
genic MMP-2. A further factor is the angiogenesis inhibitor-1 (BAI1), also known as vascu‐
lostatin, that is produced only in glial cells and neurons of normal brain but not in blood
vessels. Since vasculostatin is defnietly reduced in glioblastomas, its role in suppressing an‐
giogenesis is glioma is strongly supposed. [222-231]
9. Conclusion
There are no simple and evidently succesful protocols for therapy of primary brain tumors.
The intensive proliferation activity, the significant peritumoral infiltration and increased an‐
giogenesis altogether are responsible for the extremely high recurrence rate of gliomas. The
failure of recently administered chemotherapy arises the requirement of combination thera‐
py. Thus besides searching a highly specific tumor marker, establishing the molecular spec‐
trum of these tumors can be suggested. Supporting this theory, the mRNA expression
pattern of the invasion-related molecules was found to be highly specific for various differ‐
ent histological tumor groups. So determination of the genetic signature of invasion of a
glioma is thought to help in screening exact molecules as targets for individual chemothera‐
py. [89] Furthermore, complexity of oncotherapy with combination of antiproliferation, anti‐
invasive and antiangiogenic drugs could bring benefits in treatment effectiveness against
brain tumors in the future.
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